JP2024146897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024146897A5 JP2024146897A5 JP2024055240A JP2024055240A JP2024146897A5 JP 2024146897 A5 JP2024146897 A5 JP 2024146897A5 JP 2024055240 A JP2024055240 A JP 2024055240A JP 2024055240 A JP2024055240 A JP 2024055240A JP 2024146897 A5 JP2024146897 A5 JP 2024146897A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- cancer
- compound
- pharma
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 35
- 229910052736 halogen Inorganic materials 0.000 claims 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 30
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 30
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000002367 halogens Chemical class 0.000 claims 28
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 22
- -1 cyclic amine Chemical class 0.000 claims 19
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 17
- 125000002947 alkylene group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 5
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical group C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- YETODIXQMRZKEG-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[2,3-c]pyrrole Chemical compound C1NCC2NCCC21 YETODIXQMRZKEG-UHFFFAOYSA-N 0.000 claims 4
- QFCMBRXRVQRSSF-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole Chemical group C1NCC2CNCC21 QFCMBRXRVQRSSF-UHFFFAOYSA-N 0.000 claims 4
- UQPXYEYBUROSJF-UHFFFAOYSA-N 1,6-diazaspiro[3.3]heptane Chemical compound N1CCC11CNC1 UQPXYEYBUROSJF-UHFFFAOYSA-N 0.000 claims 4
- JAUHHUMGLNVJQI-UHFFFAOYSA-N 1,7-diazaspiro[3.4]octane Chemical compound N1CCC11CNCC1 JAUHHUMGLNVJQI-UHFFFAOYSA-N 0.000 claims 4
- OXPIFHNJGOJJQZ-UHFFFAOYSA-N 2,7-diazaspiro[3.4]octane Chemical compound C1NCC11CNCC1 OXPIFHNJGOJJQZ-UHFFFAOYSA-N 0.000 claims 4
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 claims 4
- 206010004593 Bile duct cancer Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 150000001539 azetidines Chemical group 0.000 claims 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 201000004101 esophageal cancer Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 102200006531 rs121913529 Human genes 0.000 claims 4
- 102200006539 rs121913529 Human genes 0.000 claims 4
- 102200006538 rs121913530 Human genes 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- GLUABPSZMHYCNO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,2-b]pyrrole Chemical compound N1CCC2NCCC21 GLUABPSZMHYCNO-UHFFFAOYSA-N 0.000 claims 3
- IJVGODUTGYOVKR-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-pyrrolo[3,2-b]pyridine Chemical compound N1CCCC2NCCC21 IJVGODUTGYOVKR-UHFFFAOYSA-N 0.000 claims 3
- KSCPLKVBWDOSAI-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydro-1h-pyrrolo[3,4-b]pyridine Chemical compound N1CCCC2CNCC21 KSCPLKVBWDOSAI-UHFFFAOYSA-N 0.000 claims 3
- UMIZTIYZNFUATK-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydropyrrolo[3,4-b][1,4]oxazine Chemical compound O1CCNC2CNCC21 UMIZTIYZNFUATK-UHFFFAOYSA-N 0.000 claims 3
- DAHLUHBOWUHHOX-UHFFFAOYSA-N 2,5-diazaspiro[3.4]octane Chemical compound C1NCC11NCCC1 DAHLUHBOWUHHOX-UHFFFAOYSA-N 0.000 claims 3
- ASAXTPDZLSFQSX-UHFFFAOYSA-N 2,5-diazaspiro[3.5]nonane Chemical compound C1NCC11NCCCC1 ASAXTPDZLSFQSX-UHFFFAOYSA-N 0.000 claims 3
- ZHAIMJRKJKQNQI-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.4]octane Chemical compound C1OCC11CNCC1 ZHAIMJRKJKQNQI-UHFFFAOYSA-N 0.000 claims 3
- XKEYAOJRNJYJMM-UHFFFAOYSA-N 3,6-diazabicyclo[3.2.0]heptane Chemical compound C1NCC2CNC21 XKEYAOJRNJYJMM-UHFFFAOYSA-N 0.000 claims 3
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 claims 3
- NEOIOGUWEUTYIH-UHFFFAOYSA-N 3-azabicyclo[3.2.0]heptane Chemical compound C1NCC2CCC21 NEOIOGUWEUTYIH-UHFFFAOYSA-N 0.000 claims 3
- WOBSKBVWJAJZQL-UHFFFAOYSA-N 3a,4,6,6a-tetrahydro-3h-furo[3,4-d][1,3]oxazol-2-one Chemical compound C1OCC2OC(=O)NC21 WOBSKBVWJAJZQL-UHFFFAOYSA-N 0.000 claims 3
- FOGGMWDTLLXUTO-UHFFFAOYSA-N 4,7-diazabicyclo[3.2.0]heptane Chemical compound C1CNC2CNC21 FOGGMWDTLLXUTO-UHFFFAOYSA-N 0.000 claims 3
- JDDQECMBPWVIRU-UHFFFAOYSA-N 4-azaspiro[2.4]heptane Chemical compound C1CC11NCCC1 JDDQECMBPWVIRU-UHFFFAOYSA-N 0.000 claims 3
- HOXWESKAHYABGO-UHFFFAOYSA-N 5-azaspiro[2.4]heptane Chemical compound C1CC11CNCC1 HOXWESKAHYABGO-UHFFFAOYSA-N 0.000 claims 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- UDSAJFSYJMHNFI-UHFFFAOYSA-N 2,6-diazaspiro[3.3]heptane Chemical compound C1NCC11CNC1 UDSAJFSYJMHNFI-UHFFFAOYSA-N 0.000 claims 2
- HQQVXVKQOPZRBJ-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-furo[3,4-c]pyrrole Chemical group C1OCC2CNCC21 HQQVXVKQOPZRBJ-UHFFFAOYSA-N 0.000 claims 2
- ISGOOAZVDIZEMN-UHFFFAOYSA-N 3,6-diazabicyclo[3.2.1]octane Chemical compound C1C2CNC1CNC2 ISGOOAZVDIZEMN-UHFFFAOYSA-N 0.000 claims 2
- URXNGDKBCYJULA-UHFFFAOYSA-N 4,7-diazabicyclo[3.2.1]octane Chemical compound C1C2CNC1CCN2 URXNGDKBCYJULA-UHFFFAOYSA-N 0.000 claims 2
- FIZARKJBNYKGJI-UHFFFAOYSA-N 4-azabicyclo[3.2.0]heptane Chemical compound N1CCC2CCC21 FIZARKJBNYKGJI-UHFFFAOYSA-N 0.000 claims 2
- USDIRSJFHPHMAS-UHFFFAOYSA-N ClC1=NC=C(C=2C1=NC=CN=2)F Chemical compound ClC1=NC=C(C=2C1=NC=CN=2)F USDIRSJFHPHMAS-UHFFFAOYSA-N 0.000 claims 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 239000012824 ERK inhibitor Substances 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 2
- 108010021466 Mutant Proteins Proteins 0.000 claims 2
- 239000012270 PD-1 inhibitor Substances 0.000 claims 2
- 239000012668 PD-1-inhibitor Substances 0.000 claims 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- PDGKMPLHZMPYBV-UHFFFAOYSA-N 1,2,3,6a-tetrahydropyrrolo[3,4-c]pyrrole Chemical compound N1=CC2CNCC2=C1 PDGKMPLHZMPYBV-UHFFFAOYSA-N 0.000 claims 1
- YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 claims 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 claims 1
- TUDSQZVIXYHEHF-UHFFFAOYSA-N 1-oxa-7-azaspiro[4.4]nonane Chemical compound C1CCOC21CNCC2 TUDSQZVIXYHEHF-UHFFFAOYSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- QFKVQNJEBLYEAH-UHFFFAOYSA-N 2,3,3a,4,6,6a-hexahydro-1h-furo[3,4-b]pyrrole Chemical compound C1OCC2NCCC21 QFKVQNJEBLYEAH-UHFFFAOYSA-N 0.000 claims 1
- DDVRNOMZDQTUNS-UHFFFAOYSA-N 2,7-diazaspiro[4.4]nonane Chemical compound C1NCCC11CNCC1 DDVRNOMZDQTUNS-UHFFFAOYSA-N 0.000 claims 1
- RECARUFTCUAFPV-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.5]nonane Chemical compound C1OCC11CCNCC1 RECARUFTCUAFPV-UHFFFAOYSA-N 0.000 claims 1
- RLPYXXBIHMUZRE-UHFFFAOYSA-N 4,7-diazaspiro[2.5]octane Chemical compound C1CC11NCCNC1 RLPYXXBIHMUZRE-UHFFFAOYSA-N 0.000 claims 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- VXUWETRSZDNLTC-UHFFFAOYSA-N bicyclo[1.1.1]pentan-3-ol Chemical compound C1C2CC1(O)C2 VXUWETRSZDNLTC-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004431 deuterium atom Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- YKPJEYXZEBLYCI-UHFFFAOYSA-N pyrrolo[3,4-c]pyrrole Chemical compound C1=NC=C2C=NC=C21 YKPJEYXZEBLYCI-UHFFFAOYSA-N 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025067243A JP2025111535A (ja) | 2023-03-31 | 2025-04-16 | Ｋｒａｓ阻害剤 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382315 | 2023-03-31 | ||
| EP23382315 | 2023-03-31 | ||
| EP23382531 | 2023-06-02 | ||
| EP23382531 | 2023-06-02 | ||
| EP23382857 | 2023-08-18 | ||
| EP23382857 | 2023-08-18 | ||
| EP23382985 | 2023-09-27 | ||
| EP23382985 | 2023-09-27 | ||
| EP24382267 | 2024-03-12 | ||
| EP24382267 | 2024-03-12 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067243A Division JP2025111535A (ja) | 2023-03-31 | 2025-04-16 | Ｋｒａｓ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024146897A JP2024146897A (ja) | 2024-10-15 |
| JP2024146897A5 true JP2024146897A5 (https=) | 2025-03-18 |
| JP7669556B2 JP7669556B2 (ja) | 2025-04-28 |
Family
ID=90826251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055240A Active JP7669556B2 (ja) | 2023-03-31 | 2024-03-29 | Ｋｒａｓ阻害剤 |
| JP2025067243A Pending JP2025111535A (ja) | 2023-03-31 | 2025-04-16 | Ｋｒａｓ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025067243A Pending JP2025111535A (ja) | 2023-03-31 | 2025-04-16 | Ｋｒａｓ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240368193A1 (https=) |
| EP (1) | EP4688792A1 (https=) |
| JP (2) | JP7669556B2 (https=) |
| KR (1) | KR20250163395A (https=) |
| CN (1) | CN121002032A (https=) |
| AR (1) | AR132295A1 (https=) |
| AU (1) | AU2024241889A1 (https=) |
| CL (1) | CL2025002769A1 (https=) |
| CO (1) | CO2025013134A2 (https=) |
| DO (1) | DOP2025000245A (https=) |
| IL (1) | IL323362A (https=) |
| JO (1) | JOP20250246A1 (https=) |
| MX (1) | MX2025011449A (https=) |
| PE (1) | PE20252444A1 (https=) |
| TW (1) | TWI901059B (https=) |
| WO (1) | WO2024206766A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202535880A (zh) * | 2023-10-30 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025214344A1 (zh) * | 2024-04-09 | 2025-10-16 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其在药学上的应用 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026075945A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| TW202033518A (zh) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| PT3886991T (pt) | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| CN116390923B (zh) | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| TWI880049B (zh) | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| US20240166660A1 (en) * | 2021-01-15 | 2024-05-23 | Beigene Switzerland Gmbh | Kras g12c inhibitors |
| WO2022261154A1 (en) * | 2021-06-09 | 2022-12-15 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
| CN115611923A (zh) | 2021-07-12 | 2023-01-17 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN117222654A (zh) | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| CN115785199A (zh) | 2021-09-10 | 2023-03-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| MX2024011631A (es) | 2022-03-25 | 2024-09-30 | Lilly Co Eli | Inhibidores de kras. |
-
2024
- 2024-03-29 US US18/621,388 patent/US20240368193A1/en active Pending
- 2024-03-29 PE PE2025001908A patent/PE20252444A1/es unknown
- 2024-03-29 EP EP24721007.3A patent/EP4688792A1/en active Pending
- 2024-03-29 CN CN202480023688.7A patent/CN121002032A/zh active Pending
- 2024-03-29 AU AU2024241889A patent/AU2024241889A1/en active Pending
- 2024-03-29 TW TW113112022A patent/TWI901059B/zh active
- 2024-03-29 JP JP2024055240A patent/JP7669556B2/ja active Active
- 2024-03-29 WO PCT/US2024/022154 patent/WO2024206766A1/en not_active Ceased
- 2024-03-29 KR KR1020257035985A patent/KR20250163395A/ko active Pending
- 2024-04-03 AR ARP240100807A patent/AR132295A1/es unknown
-
2025
- 2025-04-16 JP JP2025067243A patent/JP2025111535A/ja active Pending
- 2025-09-11 CL CL2025002769A patent/CL2025002769A1/es unknown
- 2025-09-14 IL IL323362A patent/IL323362A/en unknown
- 2025-09-25 CO CONC2025/0013134A patent/CO2025013134A2/es unknown
- 2025-09-26 MX MX2025011449A patent/MX2025011449A/es unknown
- 2025-09-28 JO JOJO/P/2025/0246A patent/JOP20250246A1/ar unknown
- 2025-09-29 DO DO2025000245A patent/DOP2025000245A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024146897A5 (https=) | ||
| CN117651700A (zh) | 2-氨基苯并噻唑化合物及使用方法 | |
| KR101812357B1 (ko) | Ｃｄｋ4/6의 억제제로서의 피롤로피리미딘 화합물 | |
| WO2023018812A1 (en) | Heterocyclic compounds and methods of use | |
| JP2024517693A5 (https=) | ||
| WO2023018809A1 (en) | Heterocyclic compounds and methods of use | |
| EP4384177A1 (en) | Heterocyclic compounds and methods of use | |
| JP2022543689A (ja) | Ｓｈｐ２阻害剤 | |
| EP4705293A1 (en) | Spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| JP2011516558A5 (https=) | ||
| US20240059703A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2011500774A5 (https=) | ||
| JP2015526394A5 (https=) | ||
| RU2016135637A (ru) | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение | |
| JP2013504543A (ja) | 二環ヘテロアリール類のエーテル誘導体 | |
| WO2025136346A1 (en) | Indazole containing compounds and methods of use | |
| JP2024515545A5 (https=) | ||
| RU2011109223A (ru) | ПРОИЗВОДНЫЕ 2-АЛКИЛ-6-ЦИКЛОАМИНО-3-(ПИРИДИН-4-ИЛ)ИМИДАЗОЛ[1,2-b]-ПИРИДАЗИНА, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ | |
| CN112673007A (zh) | 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物 | |
| WO2025217247A1 (en) | Tethered spiro-heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| WO2025194057A1 (en) | Macrocyclic compounds as modulators of kras and uses thereof | |
| RU2023134860A (ru) | Ингибиторы мутации her2 | |
| WO2025230862A1 (en) | Macrocyclic amino compounds as modulators of kras and uses therof | |
| WO2025230878A1 (en) | Macrocyclic compounds as modulators of kras and uses thereof | |
| CN117835976A (zh) | 杂环化合物及使用方法 |